The Menin-MLL1 inhibitor induced differentiation and loss of CD34 + /CD38 − cells in patient-derived MLL1-r + AML cells (AML#8531, AML676, and NCCHD010) in vitro. This evidence concerns the gene KMT2A and acute myeloid leukemia.